EN DE
Watch MEDIPOST Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MEDIPOST Co. Ltd (078160) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of MEDIPOST Co. Ltd stock KRW 3,576, price KRW 8,480, that is 57.8% below the price, quality 25 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7078160009

MC MEDIPOST Co. Ltd logo Thin data Nov 8, 2026

MEDIPOST Co. Ltd

078160 · KQ
Very expensive, weak quality

Our calculation puts a fair price 58% below what the stock costs today.

Low debt
Revenue last quarter +23% vs. a year ago.
Expensive Growth (revenue 5y +8.7 %/yr in KRW)
Thin margins · 4.4% net margin (TTM)
Fair value 3,576 KRW · Strongly overvalued
Quality 25/100
Negative free cash flow
Trails peers (3/9)
Narrow moat 15/100 · thin data
Thin data
⚠ Dilution
Watch MEDIPOST Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

28,437 KRW 5,500 KRW Fair Value 3,576 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 5,500 KRW – 28,437 KRW · fair‑value band 2,669 KRW – 5,337 KRW · the 8,480 KRW price screens above the 3,576 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow MEDIPOST Co. in your weekly email

Every Wednesday you see whether MEDIPOST Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases.

Show moreShow less

The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis.

In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is in completed Phase II clinical trial in South Korea, as well as in Phase I/II clinical trial in the United States for the preventative treatment of bronchopulmonary dysplasia; and NEUROSTEM that is in Phase I/IIa clinical study to treat Alzheimer's disease.

Further, the company develops SMUP-IA-01, which has completed phase I clinical trial for the treatment of osteoarthritis; and SMUP-IV-01 for the treatment of diabetic nephropathy, as well as offers nutritional and dietary supplements under the MOVITA brand name.

MEDIPOST Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.

Stock analysis

MEDIPOST Co. Ltd (078160) currently trades at 8,480 KRW, while our model-based Fair Value estimate is 3,576 KRW, 58% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: 2,669 KRW (bear) to 5,337 KRW (bull), the price of 8,480 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

MEDIPOST Co. Ltd reported revenue of 73.7B KRW in FY2025 versus 54.9B KRW in FY2021, a compound +7.6%/yr. Reported net income was −85.4B KRW in FY2025.

Key figures

Market cap 331B KRW (≈ $245M) Micro · P/S ratio 5.49 · Net margin 4.4% · Return on equity −2,667% · Return on assets (EBIT) −7.4% (5-year average) · Operating margin −26.3% · Revenue (TTM) 62.4B KRW · Revenue growth (YoY) +23.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −39% fair-value upside, at −58%, 078160 screens richer than that median.

Fair Value models

Bear 2,669 KRW Fair Value 3,576 KRW Bull 5,337 KRW
Price 8,480 KRW · Downside -57.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 3,139 KRW 4,207 KRW 6,279 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 3,139 KRW 4,207 KRW 6,279 KRW 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2020 (pandemic). Over 10 years: +7.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5.0% (2020) → −92.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

078160 screens overvalued: fair value 58% below the price. Compare with Bioneer Corporation →

Compare MEDIPOST Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2276 stocks

Beats the sector median on 3/9 measures
Overall it trails its sector peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −57.8% · Below median
Profitability
Return on assets −19.8% · Bottom 25%
Net margin (12 months) 4.4% · Below median
Operating margin (12 months) −26.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.4% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 1.33× · Cheaper than median
P/S (12 months) 5.31× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 18
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Purple Biotech Ltd KTOV 0.0100 ILS 0.0160 ILS +60% vs 078160
Cell Biotech Co 049960 14,630 KRW 15,078 KRW +3% vs 078160
AbbVie Inc ABBV $291.31 $259.62 −11% vs 078160
Biotoxtech Co 086040 2,185 KRW 1,916 KRW −12% vs 078160
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs 078160
Bioneer Corporation 064550 6,350 KRW 3,547 KRW −44% vs 078160
Eli Lilly and Company LLY $1,354 $749.92 −45% vs 078160
Panagene Inc 046210 1,071 KRW 480.36 KRW −55% vs 078160
Macrogen, Inc 038290 11,000 KRW 4,457 KRW −59% vs 078160
Pluri Inc PSTI 3.99 ILS 0.9600 ILS −76% vs 078160

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEDIPOST Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MEDIPOST Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/078160

Frequently asked questions

Is MEDIPOST Co. Ltd (078160) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 3,576 KRW versus a price of 8,480 KRW, about 58% lower (overvalued).
What is the fair value of 078160?
Our model-based fair value for MEDIPOST Co. Ltd is 3,576 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 8,480 KRW.
What is the quality score of 078160?
MEDIPOST Co. Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDIPOST Co. Ltd (078160)?
Our model-based price target is the fair value of 3,576 KRW (as of Nov 8, 2026) from 1 valuation models. Cautious scenario 2,669 KRW, optimistic scenario 5,337 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDIPOST Co. Ltd stock forecast for 2026?
Our models put fair value at 3,576 KRW, about 58% lower versus a price of 8,480 KRW (overvalued). Cautious scenario 2,669 KRW, optimistic scenario 5,337 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MEDIPOST Co. Ltd (078160)?
MEDIPOST Co. Ltd reported trailing-twelve-month revenue of about 62.4B KRW (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of MEDIPOST Co. Ltd (078160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDIPOST Co. Ltd it is 3,576 KRW per share (as of Nov 8, 2026), against a price of 8,480 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is MEDIPOST Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 078160 trades above its calculated fair value: price 8,480 KRW, fair value 3,576 KRW, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 078160?
No. The price is what the market pays today (8,480 KRW); the fair value is what the company's own numbers justify (3,576 KRW). For MEDIPOST Co. Ltd the two are 4,904 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDIPOST Co. Ltd worth?
The market values MEDIPOST Co. Ltd at about 331B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 8,480 KRW; our models calculate a fair value of 3,576 KRW per share.
What do the bullish and bearish scenarios say about 078160?
Our models span a range for MEDIPOST Co. Ltd: cautious scenario 2,669 KRW, base 3,576 KRW, optimistic 5,337 KRW per share (as of Nov 8, 2026, price 8,480 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MEDIPOST Co. Ltd (078160)?
Balance-sheet figures for MEDIPOST Co. Ltd (as of Nov 8, 2026): debt of 0.03 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 078160 from its 52-week high?
MEDIPOST Co. Ltd trades at 8,480 KRW, about 70% below its 52-week high of 28,000 KRW and 13% above the low of 7,520 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3,576 KRW is for.
Which stocks are comparable to MEDIPOST Co. Ltd?
From the same area (Healthcare) we also value Bioneer Corporation, Macrogen, Inc, Cell Biotech Co, Panagene Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDIPOST Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 8,480 KRW, calculated fair value 3,576 KRW (−58%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 078160 calculated?
We run MEDIPOST Co. Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 3,576 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. MEDIPOST Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDIPOST Co. Ltd (078160)?
The closing price on Nov 6, 2026 was 8,480 KRW. Our model-based fair value is 3,576 KRW, about 58% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDIPOST Co. Ltd right now?
The price sits above even our optimistic bull case (5,337 KRW). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,669 KRW to 5,337 KRW) leaves room in how you read the outcome.

Key figures of MEDIPOST Co. Ltd

How large is the market capitalisation of MEDIPOST Co. Ltd (078160)?
The market capitalisation of MEDIPOST Co. Ltd is 331B KRW (≈ $245M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDIPOST Co. Ltd (078160)?
The price-to-sales ratio of MEDIPOST Co. Ltd is 5.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of MEDIPOST Co. Ltd (078160)?
The net margin of MEDIPOST Co. Ltd is 4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDIPOST Co. Ltd (078160)?
The return on equity (ROE) of MEDIPOST Co. Ltd is −2,667% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDIPOST Co. Ltd (078160)?
On an EBIT basis the return on assets of MEDIPOST Co. Ltd is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDIPOST Co. Ltd (078160)?
The operating margin of MEDIPOST Co. Ltd is −26.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDIPOST Co. Ltd (078160)?
Revenue at MEDIPOST Co. Ltd is growing +23.4% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDIPOST Co. Ltd (078160)?
Earnings per share at MEDIPOST Co. Ltd are growing +975% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does MEDIPOST Co. Ltd (078160) generate?
The free cash flow of MEDIPOST Co. Ltd is −60.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MEDIPOST Co. Ltd (078160) carry?
The net debt of MEDIPOST Co. Ltd is 32.9B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MEDIPOST Co. Ltd in the live analysis

One click puts MEDIPOST Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.